Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
[Preparation and identification of monoclonal antibodies against human LAG3 by immunizing mice with recombinant eukaryotic cell antigens].
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
December 2024
Department of Medical Experimental Center, Northern Jiangsu People's Hospital, Yangzhou 225001, China. *Corresponding author, E-mail: yyue_king
Objective To prepare mouse anti-human lymphocyte activation gene 3 (LAG3) monoclonal antibody (mAb) and perform immunological identification of the antibody. Methods BALB/c mice were immunized with LAG3-mLumin-3T3 cells, which stably express the extracellular and transmembrane regions of human LAG3 in mouse 3T3 cells. The secretion of anti-human LAG3 antibodies in mouse serum was assessed using flow cytometry and immunofluorescence.
View Article and Find Full Text PDFAn Emerging Toolkit of Ho Sensitized Lanthanide Nanocrystals with NIR-II Excitation and Emission for Bioimaging.
J Am Chem Soc
January 2025
Department of Chemistry, Laboratory of Advanced Materials, State Key Laboratory of Molecular Engineering of Polymers, Shanghai Key Laboratory of Molecular Catalysis and Innovative Materials, Fudan University, Shanghai 200433, China.
Optical imaging in the second near-infrared window (NIR-II, 1000-1700 nm) holds great promise for biomedical detection due to reduced tissue scattering and autofluorescence. However, the rational design of NIR-II probes with superior excitation wavelengths to balance the effects of tissue scattering and water absorption remains a great challenge. To address this issue, here we developed a series of Ho-sensitized lanthanide (Ln) nanocrystals (NaYF: Ho, Ln@NaYF) excited at 1143 nm, featuring tunable emissions ranging from 1000 to 2200 nm for bioimaging.
View Article and Find Full Text PDFHDAC3 inhibitors induce drug resistance by promoting IL-17 A production by T cells.
Sci Rep
December 2024
Hebei Key Laboratory for Chronic Diseases, Tangshan Key Laboratory for Preclinical and Basic Research on Chronic Diseases, School of Basic Medical Sciences, North China University of Science and Technology, Tangshan, 063210, China.
HDAC3 has been demonstrated to play a crucial role in the progression of various tumors and the differentiation and development of T cells. However, its impact on peripheral T cells in the development of murine lung cancer remains unclear. In this experiment, a subcutaneous lung tumor model was established in C57BL/6 mice, and tumor-bearing mice were treated with the specific inhibitor of HDAC3, RGFP966, at different doses to observe changes in tumor size.
View Article and Find Full Text PDFActivin A promoted the anti-tumor effect of ActRIIA CD8 T cells in mouse hepatoma.
Cancer Med
January 2025
Department of Clinical Laboratory, Affiliated Hospital of Shandong Second Medical University, Weifang, China.
Background: Activin A, a noteworthy member of the TGF-β superfamily. Activin A can regulate the biological functions of various immune cells, such as macrophages, neutrophils, NK cells, etc. The purpose of this study is to investigate the regulatory effect and related mechanisms of activin A on CD8 T cells.
View Article and Find Full Text PDFCryoablation plus chemotherapy regimen enhance anti-tumor immune response in a mouse model of Lewis lung cancer.
Int J Hyperthermia
December 2024
Oncology Department, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, China.
Background: Cryoablation (cryo) is a local anti-tumor method and activation of immunity is one of its mechanisms, but it is affected by many factors. Numerous studies have proved that combination therapy based on cryo can activate immunity more effectively and synergistically. Cryo combined with chemotherapy(chemo) has been proven to improve the quality of life and prolong survival of tumor patients, but the immune effect is still unclear.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!